# Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis

> **NCT00599274** · — · COMPLETED · sponsor: **Biogen** · enrollment: 136 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Interferon beta-1a
- **DRUG:** Interferon beta-1a

## Key facts

- **NCT ID:** NCT00599274
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2002-08
- **Primary completion:** —
- **Final completion:** 2003-05
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2010-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00599274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00599274, "Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00599274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*